What Is Bacillomycin? Definition and What Research Reports

Definition

Bacillomycin is the name given to a family of cyclic lipopeptides — compact, ring-shaped peptide molecules that carry a fatty-acid (lipid) tail — produced naturally by several bacteria in the Bacillus subtilis species complex, including Bacillus amyloliquefaciens, Bacillus velezensis and related soil and plant-associated strains. Bacillomycins are classified within the iturin group of Bacillus lipopeptides and are assembled by large multi-enzyme nonribosomal peptide synthetase complexes rather than by ribosomal translation, which is why their building blocks include amino acids and lipid components not found in ordinary proteins. In the published literature the term appears almost entirely in microbiology, plant-pathology and biocontrol contexts: bacillomycin is described as one of the antifungal metabolites that certain Bacillus strains secrete, and it is usually discussed alongside its structural relatives such as iturin A, surfactin and the fengycins. A review of antimicrobial lipopeptides from Bacillus spp. grouped bacillomycin with these other major lipopeptide families and summarised their reported antimicrobial properties (PMID 35611728).

What Class of Molecule It Is

Bacillomycin is a non-ribosomal cyclic lipopeptide, not a linear signalling peptide and not a peptide hormone analogue. Structurally, members of the iturin family share a cyclic peptide head joined to a β-amino fatty acid chain, and individual variants are distinguished by amino-acid substitutions in the ring and by the length of the lipid tail. That naming convention is why the literature refers to specific congeners: a 2022 study on maize kernels worked with bacillomycin D-C16, the variant carrying a sixteen-carbon fatty-acid chain, and reported that it inhibited growth of Fusarium verticillioides and reduced production of the mycotoxin fumonisin B₁ (PMID 35082038).

Where It Comes From

Bacillomycin production is a strain-level trait rather than a universal feature of the genus. A large comparative analysis mapped the distribution of secondary-metabolite biosynthetic gene clusters across the Bacillus subtilis species complex and reported that lipopeptide and other metabolite clusters were unevenly distributed among lineages (PMID 33688015). Producing strains have been recovered from many environments. Researchers isolating endophytic Bacillus strains from pearl millet (Pennisetum glaucum) reported both plant-growth-promoting traits and antifungal activity among the isolates (PMID 31642002), and a separate study characterised a marine-derived strain, Bacillus velezensis NDB, for its antimicrobial biological activity (PMID 38421449).

How the Term Is Used in Peptide Research

In peptide-focused literature, "bacillomycin" functions mainly as a chemical identifier — a label for one of the antifungal lipopeptides detected when a Bacillus culture extract is analysed, typically by mass spectrometry, or when a genome is screened for biosynthetic gene clusters. Three usages recur:

• As an analytical marker. Studies that profile Bacillus culture supernatants list bacillomycin among the non-volatile antifungal compounds detected; one investigation separated volatile from non-volatile antifungal compounds produced by Bacillus spp. strains and characterised their activity against fungal targets (PMID 37543004).
• As a strain-performance metric. Comparative work on Bacillus velezensis UTB96 reported improved lipopeptide production relative to the well-studied reference strain B. velezensis FZB42 (PMID 36363818), illustrating how bacillomycin output is used to rank candidate strains.
• As a regulated biosynthetic product. Genetic studies treat bacillomycin as the readout of a regulatory network; one paper examined the roles of CodY, ComA, DegU and Spo0A in controlling lipopeptide biosynthesis in Bacillus amyloliquefaciens fmbJ (PMID 33460520).

Bacillomycin is not used in the literature as a research peptide administered to animals or humans for physiological endpoints. It appears in microbiology, fermentation science and crop-protection research, and readers encountering the name in a peptide glossary should understand it as a bacterial natural product rather than a candidate therapeutic.

What the Published Literature Reports

The reported activity of bacillomycin-type lipopeptides is predominantly antifungal and antimicrobial. The maize-kernel study cited above reported inhibition of Fusarium verticillioides growth and reduced fumonisin B₁ production by bacillomycin D-C16 (PMID 35082038). Work on the marine isolate B. velezensis NDB analysed antimicrobial biological activity of the strain and its metabolites (PMID 38421449), while a study of Bacillus velezensis 83 interacting with the anthracnose fungus Colletotrichum gloeosporioides described a stress-resistant bacterial phenotype with antibiosis capacity, which the authors likened to a Greek phalanx-style formation (PMID 38199003).

Beyond antifungal endpoints, mass spectrometry-guided genome mining combined with virtual screening was applied to secondary metabolites of Bacillus velezensis W1 to look for acaricidal activity (PMID 35478879), showing that lipopeptide-producing strains are also screened against invertebrate targets. Results in whole-plant systems have not always been uniformly positive: one study reported that a combination of two Bacillus strains suppressed the root-knot nematode Meloidogyne incognita and fungal pathogens but did not enhance plant growth (PMID 34689397). Taken together, the literature describes bacillomycin as one component of a broader antimicrobial metabolite arsenal whose measured effects depend on the strain, the target organism and the test system.

Terms Frequently Seen Alongside Bacillomycin

Bacillomycin Safety Evaluation: What Studies Report

Safety information in the cited set is limited and non-clinical. A 2018 paper isolated a new cyclic lipopeptide from Bacillus amyloliquefaciens HAB-2 and included a safety evaluation of the purified compound as part of its characterisation (PMID 29933991). None of the verified papers assembled for this entry described administration of bacillomycin to humans, and none reported human adverse-event data; the work summarised here was laboratory microbiology, fermentation and plant-protection research (PMID 37543004, PMID 34689397). This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question, and note that a compound described in agricultural microbiology literature has no established human use profile in the papers cited.

Key Takeaways

• Bacillomycin is a cyclic lipopeptide of the iturin family, made by Bacillus bacteria through nonribosomal peptide synthesis (PMID 35611728).
• Production is strain-dependent and traceable to specific biosynthetic gene clusters whose distribution researchers mapped across the B. subtilis complex (PMID 33688015).
• The most commonly reported activity is antifungal; one study reported inhibition of Fusarium verticillioides and reduced fumonisin B₁ by bacillomycin D-C16 (PMID 35082038).
• Effects measured in isolation did not always translate to plant-level benefits, as in the study where two Bacillus strains suppressed pathogens without enhancing plant growth (PMID 34689397).

References

• [Advances in several important antimicrobial lipopeptids from Bacillus spp] (Chinese Journal of Biotechnology, 2022)
• Bacillomycin D-C16 inhibits growth of Fusarium verticillioides and production of fumonisin B1 in maize kernels (Pesticide Biochemistry and Physiology, 2022)
• Phylogenetic Distribution of Secondary Metabolites in the Bacillus subtilis Species Complex (mSystems, 2021)
• Plant growth promoting and antifungal activity in endophytic Bacillus strains from pearl millet (Pennisetum glaucum) (Brazilian Journal of Microbiology, 2020)
• Analysis of antimicrobial biological activity of a marine Bacillus velezensis NDB (Archives of Microbiology, 2024)
• Detection and evaluation of volatile and non-volatile antifungal compounds produced by Bacillus spp. strains (Microbiological Research, 2023)
• Characterization of Bacillus velezensis UTB96, Demonstrating Improved Lipopeptide Production Compared to the Strain B. velezensis FZB42 (Microorganisms, 2022)
• CodY, ComA, DegU and Spo0A controlling lipopeptides biosynthesis in Bacillus amyloliquefaciens fmbJ (Journal of Applied Microbiology, 2021)
• The combination of two Bacillus strains suppresses Meloidogyne incognita and fungal pathogens, but does not enhance plant growth (Pest Management Science, 2022)
• Combined mass spectrometry-guided genome mining and virtual screening for acaricidal activity in secondary metabolites of Bacillus velezensis W1 (RSC Advances, 2021)
• A new cyclic lipopeptide isolated from Bacillus amyloliquefaciens HAB-2 and safety evaluation (Pesticide Biochemistry and Physiology, 2018)
• Response of Bacillus velezensis 83 to interaction with Colletotrichum gloeosporioides resembles a Greek phalanx-style formation: A stress resistant phenotype with antibiosis capacity (Microbiological Research, 2024)